Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.

Pneumoproteins Expression in the Organ Donor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02032069
Recruitment Status : Completed
First Posted : January 9, 2014
Last Update Posted : March 15, 2016
Information provided by (Responsible Party):
Asmae Belhaj, University Hospital of Mont-Godinne

Brief Summary:
Primary graft dysfunction, a form of reperfusion pulmonary edema that occurs early after lung transplantation, shares key clinical and pathological features with acute lung injury and its more severe form, the acute respiratory distress syndrome. However, in contrast to acute lung injury/acute respiratory distress syndrome, in which biomarkers in plasma, urine and lung edema fluid have prognostic and pathogenetic value, the role of biomarkers in primary graft dysfunction has been less thoroughly explored. We will try in this study de determine the rule of pneumoproteins in the donor organ on the pulmonary edema in the recipient.

Condition or disease Intervention/treatment
Primary Graft Dysfunction Other: no intervention

Layout table for study information
Study Type : Observational
Actual Enrollment : 20 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Pneumoproteins Expression in the Organ Donor
Study Start Date : January 2013
Actual Primary Completion Date : January 2016
Actual Study Completion Date : January 2016

Group/Cohort Intervention/treatment
Non Heart Beating Donors
Other: no intervention
Brain death donors
Other: no intervention

Primary Outcome Measures :
  1. Number of Recipient with primary graft dysfunction [ Time Frame: one year ]

Biospecimen Retention:   Samples With DNA
lung tissues and serum

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   5 Years to 70 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Organ donors and lung recipients

Inclusion Criteria:

All the organ donors for lung grafts.

Exclusion Criteria:


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02032069

Layout table for location information
CHU Mont-Godinne
Yvoir, Namur, Belgium, 5530
Sponsors and Collaborators
University Hospital of Mont-Godinne

Layout table for additonal information
Responsible Party: Asmae Belhaj, MD, University Hospital of Mont-Godinne Identifier: NCT02032069    
Other Study ID Numbers: B406201112693
First Posted: January 9, 2014    Key Record Dates
Last Update Posted: March 15, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Primary Graft Dysfunction
Reperfusion Injury
Vascular Diseases
Cardiovascular Diseases
Postoperative Complications
Pathologic Processes